GLP1R and chronic kidney disease: In adults with new onset type 2 diabetes, GLP‐1 receptor agonist and SGLT‐2 inhibitor utilization has markedly increased, coordinating with evolving guidelines that emphasize cardiovascular and chronic kidney disease management.